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ABSTRACT
Regulation of cell death is crucial for the response of cancer cells to
drug treatments that cause arrest in mitosis, and is likely to be
important for protection against chromosome instability in normal
cells. Prolonged mitotic arrest can result in cell death by activation of
caspases and the induction of apoptosis. Here, we show that X-
linked inhibitor of apoptosis (XIAP) plays a key role in the control of
mitotic cell death. Ablation of XIAP expression sensitises cells to
prolonged mitotic arrest caused by a microtubule poison. XIAP is
stable during mitotic arrest, but its function is controlled through
phosphorylation by the mitotic kinase CDK1–cyclin-B1 at S40.
Mutation of S40 to a phosphomimetic residue (S40D) inhibits binding
to activated effector caspases and abolishes the anti-apoptotic
function of XIAP, whereas a non-phosphorylatable mutant (S40A)
blocks apoptosis. By performing live-cell imaging, we show that
phosphorylation of XIAP reduces the threshold for the onset of cell
death in mitosis. This work illustrates that mitotic cell death is a form
of apoptosis linked to the progression of mitosis through control by
CDK1–cyclin-B1.
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INTRODUCTION
Anti-cancer drugs such as microtubule poisons arrest or delay
cells in mitosis due to the action of the mitotic or spindle assembly
checkpoint. This checkpoint normally prevents anaphase from
occurring before all chromosomes are correctly bi-orientated on the
metaphase spindle by inhibition of the anaphase-promoting
complex or cyclosome (APC/C), a large E3 ubiquitin ligase
complex that targets mitotic regulators such as securin and cyclin
B1 for destruction by the proteasome (Primorac and Musacchio,
2013). Cells that are arrested for a prolonged period in mitosis can
undergo cell death through the process of apoptosis (Allan and
Clarke, 2007; Gascoigne and Taylor, 2008). The propensity for
apoptosis is increased by the duration of the mitotic arrest (Bekier
et al., 2009; Huang et al., 2009), whereas exit from mitosis
generally reduces sensitivity to anti-mitotic drugs (Brito and
Rieder, 2006; Gascoigne and Taylor, 2008). Apoptosis can
still occur after release from a prolonged delay in mitosis after
longer-term changes, including activation of signalling pathways
and new protein expression (Colin et al., 2015; Uetake and Sluder,
2010).
The intrinsic apoptotic pathway is activated when cytochrome c
is released from mitochondria into the cytosol, where it forms a
complex with Apaf-1 leading to the recruitment and activation of
caspase-9, a cystyl-aspartame endoprotease. Caspase-9 in turn
cleaves and activates the effector caspases-3 and -7, which act on
multiple substrates to bring about the cellular changes associated
with apoptosis, including cellular blebbing, chromatin
condensation and internucleosomal DNA fragmentation
(Budihardjo et al., 1999). Apoptosis is controlled during mitosis
by protein phosphorylation and the destruction of regulators
mediated by the ubiquitin proteasome pathway; these
mechanisms couple the control of apoptosis to the progression of
mitosis (Clarke and Allan, 2009). Caspase-9 is phosphorylated at
an inhibitory site in mitosis by CDK1–cyclin-B1, the major mitotic
protein kinase, which thereby restrains apoptosis during normal
mitosis and the initial stages of mitotic arrest. If metaphase is not
successfully resolved, then apoptosis is initiated during a prolonged
mitotic arrest when the apoptotic signal overcomes the threshold set
by caspase-9 phosphorylation (Allan and Clarke, 2007).
Conversely, the apoptotic signal is initiated when
phosphorylation of the anti-apoptotic protein Mcl-1 at T92 by
CDK1–cyclin-B1 causes it to be degraded during a delay in mitosis
(Harley et al., 2010; Wertz et al., 2011). Stabilisation of Mcl-1 by
abolition of T92 phosphorylation or mutation of a destruction box
(D-box) that is recognised by the APC/C inhibits apoptosis induced
by microtubule poisons (Harley et al., 2010). In addition, the
related anti-apoptotic proteins Bcl-2 and Bcl-xL (encoded by
BCL2L1) are phosphorylated and appear to be partially inhibited
during mitosis (Terrano et al., 2010). The slow degradation of
cyclin B1 even when the spindle assembly checkpoint is active can
lead eventually to inactivation of CDK1–cyclin-B1 and slippage
out of mitosis (Brito and Rieder, 2006). Whether or not apoptosis is
initiated during mitotic arrest is likely to depend upon relative
changes in the activities of CDK1–cyclin-B1 and regulators of
apoptosis during the mitotic arrest (Allan and Clarke, 2007;
Gascoigne and Taylor, 2008).
Although caspase-3 and caspase-7 do not appear to be
regulated directly during mitosis by phosphorylation, these
enzymes might also be controlled through interacting proteins.
One candidate is X-linked inhibitor of apoptosis (XIAP), a protein
of the IAP family that is capable of inhibiting activated caspases-
3, -7 and -9 by direct binding (Deveraux et al., 1999; Takahashi
et al., 1998). XIAP can also function as an E3 ubiquitin ligase
and as a signal transduction intermediate (Eckelman et al., 2006;
Lu et al., 2007). XIAP is overexpressed in a number of cancer
cell lines, and its overexpression correlates with increased
resistance to chemotherapeutic drugs, including inhibitors of
mitosis (Durie et al., 2011; Holcik et al., 2000; Tamm et al.,
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XIAP is regulated acutely by post-translational modifications that
can determine sensitivity to cellular stresses: phosphorylation at S87
by Akt proteins reduces XIAP auto-ubiquitylation and stabilises the
protein in cisplatin-treated cells (Dan et al., 2004), whereas
phosphorylation at S430 by TANK-binding kinase 1 (TBK1) or
the IκB kinase IKKε results in the auto-ubiquitylation and
subsequent proteasomal degradation of XIAP after viral infection
of cells (Nakhaei et al., 2012). However, it has been unclear whether
regulation of XIAP plays a role in controlling apoptosis during
mitosis. In this study, we show that XIAP is phosphorylated at
specific sites during mitosis by CDK1–cyclin-B1, which inhibits
the anti-apoptotic activity of XIAP and makes mitotic cells more
sensitive to pro-apoptotic signals. Thus, XIAP plays a key role in
coupling the control of apoptosis to the progression of mitosis.
RESULTS
XIAP restrains apoptosis in response to prolonged mitotic
arrest
We tested the role of human XIAP in the control of apoptosis in
response to the disruption of mitosis. We found that knockdown of
XIAP in U2OS cells by small interfering RNA (siRNA) promoted
the cleavage and activation of caspase-3, a major effector of
apoptosis (Fig. 1A,B; Fig. S1A), and caused sub-G1 apoptotic
fragmentation of DNA (Fig. 1C; Fig. S1B) after prolonged
treatment of the cells with nocodazole, a microtubule poison that
prevents mitotic spindle assembly and arrests cells in mitosis.
Entirely consistent with these results, there was increased active
caspase-3 and sub-G1 DNA fragmentation in XIAP−/− HCT116
cells compared to that seen in wild-type cells after prolonged
treatment with nocodazole (Fig. S1C,D).
XIAP is phosphorylated during mitosis
These results established that XIAP plays a role in the control of
apoptosis in response to prolonged mitotic arrest. We did not,
however, observe any periodic changes in the levels of the protein
during the cell cycle (Fig. S2A). Similarly, the level of XIAP was
maintained during a prolonged mitotic arrest until exit from mitosis
and the induction of apoptosis (Fig. S2B). To determine whether
XIAP is regulated post-translationally by phosphorylation during
mitosis, we treated HeLa and U2OS cells with nocodazole and
compared isolated rounded-up mitotic cells with adherent
interphase cells. Modification of XIAP leading to retardation of
the protein was not readily detected on western blots of conventional
SDS-PAGE gels (Fig. 2A). However, modification of XIAP in
mitotic cells was clearly apparent when gels were supplemented
with PhosTag, an acrylamide-bound ligand that preferentially
retards the migration of phosphorylated proteins (Kinoshita et al.,
2006). There was one major and one minor retarded form of XIAP
in rounded-up mitotic cells that was not present in adherent
interphase cells also treated with nocodazole nor in untreated
asynchronous cells, demonstrating that XIAP was phosphorylated
on at least two sites specifically during mitosis, with one site
predominating (Fig. 2A). XIAP was also phosphorylated in mitotic
HCT116 and DLD1 human colorectal cancer cells with a very
similar pattern of phosphorylated forms (Fig. 2B).
The mitotic phosphorylation of XIAP was reversed in parallel
with cyclin B1 degradation when U2OS cells were released from
mitotic arrest by washing out nocodazole. Dephosphorylation of
XIAP was prevented by the proteasome inhibitor MG132, which
prevents the degradation of cyclin B1 even in the absence of the
checkpoint signal and maintains cells in mitosis (Fig. 2C). When
mitotically arrested cells were maintained in nocodazole having
been synchronised in the period of the arrest, phosphorylated forms
of XIAP progressively accumulated over 2–6 h. MG132 did not
alter the pattern of phosphorylated forms during mitotic arrest,
indicating that both hypo- and hyper-phosphorylated XIAP were
stable during the period of arrest (Fig. 2D).
Purified recombinant XIAP expressed as a fusion protein with
glutathione-S-transferase (GST–XIAP) was also phosphorylated in
Fig. 1. Endogenous XIAP restrains apoptosis in response to mitotic
arrest. Knockdown of endogenous XIAP results in increased caspase-3
activity and apoptosis in response to prolongedmitotic arrest. U2OS cells were
either untransfected (Unt), transfected with siRNA directed against luciferase,
as control (Luc), or against XIAP (siX) for 48 h and then either untreated
(asynchronous, As) or treated with 250 ng/ml nocodazole for a further 48 h
(Noc). (A,B) Generation of active, cleaved caspase-3 was analysed by
(A) SDS-PAGE and western blotting, or (B) fluorescence microscopy. In B, at
least 300 cells were counted for each category in every experiment (n=4).
(C) Apoptosis was analysed by sub-G1 DNA content by flow cytometry (n=3).
Results in B and C represent mean±s.d. *P<0.05; NS, non-significant
difference (Student’s unpaired t-test).
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a mitotic HeLa cell extract, with one major retarded form observed
on PhosTag gels that accumulated over 30 min (Fig. 2E). Formation
of phosphorylated XIAP form was inhibited by calf intestinal
phosphatase (CIP) or upon inhibition of cyclin-dependent kinases
(CDKs) by purvalanol A (Fig. 2F), indicating that mitotic
phosphorylation of this major site is dependent on CDK1 in
complex with cyclin B1 rather than cyclin A, which is lost from
mitotically arrested cells prior to preparation of the extract.
Identification of sites of mitotic phosphorylation in XIAP
HumanXIAP contains four serine and threonine residues (S40, S87,
T180 and T359) that are followed immediately by a proline residue,
a characteristic of phosphorylation sites targeted by proline-directed
kinases such as CDK1–cyclin-B1. S40 has been identified in a
global analysis of phosphorylation sites (Mertins et al., 2013) and
S87 has been shown to be phosphorylated by Akt proteins (Dan
et al., 2004). To analyse these potential mitotic phosphorylation
Fig. 2. XIAP is phosphorylated in mitotically arrested cells. (A) Analysis of XIAP phosphorylation on PhosTag gels. HeLa and U2OS cells were treated with
100 ng/ml nocodazole for 17 h and harvested as either non-adherent nocodazole mitotic (NocM) or nocodazole adherent interphase (NocAd) samples. Untreated
asynchronous cells (labelled A) were used as a control. Samples were analysed by SDS-PAGE with or without the addition of PhosTag (PT) as indicated
followed by western blotting using the indicated antibodies. *denotes a non-specific band detected by the anti-XIAP antibody. (B) XIAP is phosphorylated in
mitotically arrested cells. U2OS, HCT116 and DLD-1 cells were treated with 100 ng/ml nocodazole for 17 h. The non-adherent nocodazole-treated mitotic
(M) samples were collected and analysed in comparison with samples from untreated asynchronous cells (labelled A), and analysed. (C) XIAP phosphorylation is
mitosis specific and the protein is dephosphorylated as cells exit mitosis. U2OS cells were either untreated (labelled A) or treated with 100 ng/ml nocodazole for
17 h before the rounded up cells were either lysed, or re-plated in nocodazole-free medium in the absence or presence of 10 μM of the proteasome inhibitor
MG132 for a further 1, 2 or 4 h. (D) XIAP is continuously phosphorylated during mitosis and the phosphorylated form is stable. U2OS cells were either
untreated (labelled A) or pre-treated with 10 μM MG132 for 2 h, before adding 100 ng/ml nocodazole to the medium and leaving for 2 h. The rounded up mitotic
cells were then isolated, and either lysed or re-plated in the same medium for a further 2 or 4 h. The floating cells were collected at the end of the timecourse.
(E) Recombinant GST–XIAP is phosphorylated in mitotic cell extract. Asynchronous (labelled A) and nocodazole-treated mitotic (M) HeLa cell extracts were
incubated with recombinant GST-tagged XIAP protein for the indicated time. (F) Phosphorylation of GST–XIAP is inhibited by a CDK inhibitor or phosphatase.
In vitro phosphorylation reaction inmitotic (M) cell extracts was carried out for 30 min in the presence of 10 μMpurvalanol A (PA), 0.4 U calf intestinal phosphatase
(CIP), phosphatase buffer (–), an ATP-regenerating system (ATP) or both an ATP-regenerating system and CIP (A/C). A lysate prepared from untreated
asynchronous cells (labelled A) was used as a control.
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sites, we mutated each residue to a non-phosphorylatable alanine
residue and produced the resulting proteins by in vitro transcription
and translation (IVT) in mammalian reticulocyte lysate. When
incubated in mitotic HeLa cell extract, the wild-type, S87A, T180A
and T359A proteins were all phosphorylated whereas mutation of
S40 abolished the formation of the predominant phosphorylated
form (Fig. 3A), indicating that this residue was the major
phosphorylation site.
In another approach to determine the site(s) of mitotic
phosphorylation, XIAP stably expressed as a fusion with green
fluorescent protein (GFP–XIAP) was immunoprecipitated from
mitotic nocodazole-treated U2OS cells. We confirmed that the
protein was indeed phosphorylated in mitosis, exhibiting one major
and one minor phosphorylated form (Fig. 3B), before analysis of
tryptic peptides by nano liquid chromatography tandem mass
spectrometry (nano LC-MS/MS) on a LTQ-Obitrap Velos mass
spectrometer in combination with a neutral loss scan on a 4000
QTRAP mass spectrometer to detect phosphorylated peptides. Two
phosphorylation sites were identified, with a major peptide
phosphorylated on S40 and a less abundant peptide
phosphorylated on T180 (Fig. 3C). Taking into account the
proportion of modified XIAP detected on PhosTag gels, this data
shows that ∼50% of XIAP is phosphorylated at S40 in cells arrested
in mitosis, with additional phosphorylation at T180 at a lower
stoichiometry.
XIAP is phosphorylated at S40 in mitosis
To facilitate analysis of the phosphorylation of S40 in XIAP, a
specific polyclonal antibody was raised by inoculation with a
synthetic peptide that included the phosphorylated site. Antibodies
were purified from serum by negative selection against the
dephosphorylated peptide followed by positive selection against
the phosphopeptide (denoted the pS40 antibody). Selectivity was
tested on dot blots where bovine serum albumin (BSA)-conjugated
peptides were probed using purified antibodies (Fig. 4A). The pS40
antibody detected IVT XIAP that had been phosphorylated in
mitotic HeLa cell extracts, whereas the S40A mutant was not
detected. Thus, the antibody is specific for phosphorylated S40 and
no other phosphorylation site in XIAP (Fig. 4B). Endogenous XIAP
phosphorylated on S40 was detected in U2OS cells arrested in
mitosis with nocodazole; the specific polypeptide was identified
through its disappearance upon prior depletion of XIAP by siRNA
transfection (Fig. 4C).
We confirmed that S40 was phosphorylated in GFP–XIAP
expressed in U2OS cells arrested in mitosis with nocodazole.
Analysis of the migration of GFP–XIAP on PhosTag gels (Fig. 4D)
showed that mutation of S40 inhibited the formation of not only the
major phosphorylated form but also other minor phosphorylated
forms. This indicates that S40 is necessary for phosphorylation at
one or more of the less abundant sites, most likely including T180.
GFP–XIAP was phosphorylated on S40 in mitotic U2OS cells but
Fig. 3. Identification of sites in XIAP phosphorylated in mitosis. (A) In vitro translated (IVT) XIAP is phosphorylated in mitotic cell extract. Wild-type (wt) and
four mutant XIAP proteins were expressed in vitro to a similar level by IVT and added to extracts from asynchronous (labelled A) or mitotically arrested HeLa cells
to a level much greater than endogenous XIAP protein. Nocodazole-treated mitotic extract (M) was also incubated with wild-type protein in the presence of
calf intestinal phosphatase (CIP) or phosphatase storage buffer [CIP(−)] to confirm the phosphorylation. Reactionswere terminated by the addition of 2× SDS lysis
buffer, and the samples were analysed by SDS-PAGE with or without the addition of PhosTag (PT) as indicated followed by western blotting. (B,C) GFP-tagged
XIAP is mitotically phosphorylated at S40. (B) U2OS cells that were either untransfected (Unt) or stably expressing GFP-tagged wild-type XIAP (wt) were
treated with 100 ng/ml nocodazole for 17 h. The floating mitotic cells were collected at the end of the treatment and analysed by PhosTag SDS-PAGE and western
blotting. (C) GFP–XIAPwas precipitated from 2.2 mg cell lysate of mitotically arrested U2OS XIAP wild-type cells that had been treated with 100 ng/ml nocodazole
for 24 h. GFP–XIAP was immunoprecipitated using GFP-Trap beads and analysed by mass spectrometry of tryptic peptides.
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Fig. 4. XIAP is phosphorylated at S40 inmitotic cells. (A) An antibody generated against pS40 XIAP is specific for the phosphopeptide. Decreasing amounts of
the non-phospho-peptide (NP), phospho-peptide (P) and BSA control were spotted onto nitrocellulose membranes. The membranes were immunoblotted with
1:500 of the diluted phospho-antibody purified from serum. (B) The pS40 antibody specifically recognises XIAP phosphorylated at S40. Wild-type (wt) and
S40Amutant XIAP protein were generated using IVT, and the reactionmix for each protein was incubated with either asynchronous (labelled A) or mitotic arrested
(M) HeLa cell extract. Samples were analysed by SDS-PAGE and western blotting. The IVT reaction mix incubated without vector DNA was used as an extra
negative control (IVT lysate), which showed that the non-specific band (*) was a protein present in the reticulocyte lysate that was phosphorylated by HeLamitotic
extract. (C) Endogenous XIAP is phosphorylated at S40 in cells. U2OS cells were transfected with siRNA against XIAP or Luciferase (Luc). At 48 h post
transfection, cells were either untreated (labelled A) or treated with 250 ng/ml nocodazole for 24 h (NM). All cells were collected from untreated samples and the
floating cells were collected from nocodazole-treated samples. Cells were lysed, analysed by SDS-PAGE and immunoblotted with the anti-pS40 antibody.
Phosphorylated XIAP, which is ablated by the specific siRNA, is indicated by an arrow. (D–F) S40 is required for XIAP phosphorylation in cells. U2OS cells which
were untransfected (Unt) or stably expressing GFP–XIAP wild-type (wt) or S40A were either untreated (labelled A) or treated with 100 ng/ml nocodazole (M) for
17 h. The floating cells were collected from nocodazole-treated samples. All cell lysates were analysed by SDS-PAGE and immunoblotted with indicated
antibodies. In D, samples were analysed on a PhosTag (PT) gel. In E, adherent interphase cells (NAd) from nocodazole-treated samples were also analysed. In F,
cell lysates were incubated with GFP-Trap beads and GFP-tagged proteins were immunoprecipitated (pulldown, PD) from the samples. Lysates that were not
incubated with beads were used as input samples. eV, empty vector.
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not in untreated adherent interphase cells or nocodazole-treated
adherent cells (Fig. 4E). We unequivocally identified this
phosphorylated form as GFP–XIAP by its immunoprecipitation
from cell extracts prior to western blotting (Fig. 4F).
XIAP is phosphorylated at S40 by CDK1–cyclin-B1
The previous observation that purvalanol A inhibited the
phosphorylation of GST–XIAP in mitotic HeLa cell extract
(Fig. 2F) indicated that phosphorylation was dependent on a
CDK1–cyclin-B1. Similarly, phosphorylation of IVT XIAP
incubated in mitotic HeLa cell extract and analysed on a PhosTag
gel (Fig. 5A) was inhibited by purvalanol A and RO3306, a more
selective inhibitor that specifically targets CDK1 and not DYRK1A
at the concentration used (Vassilev et al., 2006). We confirmed that
CDK inhibitors, but not other kinase inhibitors, including
wortmannin, inhibited the phosphorylation of S40 in XIAP in
mitotic extracts (Fig. 5B). Futhermore, XIAP was phosphorylated
on S40 in a time-dependent manner upon incubation with purified
CDK1–cyclin-B1 (Fig. 5C), showing that this kinase catalyses the
phosphorylation of XIAP directly.
Mutation of S40 to an aspartate residue inhibits XIAP binding
to active effector caspases
XIAP is perhaps best known for its ability to bind to and inhibit
activate caspases (Deveraux et al., 1999; Takahashi et al., 1998). To
test whether mitotic phosphorylation of XIAP at S40 could affect
this function, we carried out an in vitro binding assay utilising a
potentially phosphomimetic aspartate mutant (S40D) as a surrogate
for phosphorylated XIAP and comparing its ability to bind cleaved
effector caspases with that of the non-phosphorylatable mutant
S40A. GFP–XIAP S40D and S40A proteins produced in stably
transfected U2OS cells were incubated with HeLa cell extract
(S100) pretreated with cytochrome c and dATP to generate cleaved
caspases (Li et al., 1997). Western blotting analysis of proteins co-
precipitating from the extract demonstrated that XIAP S40D was
less efficient at binding to cleaved caspase-7 and cleaved caspase-3
than the S40A protein (Fig. 6). In contrast, both XIAP proteins
exhibited a similar ability to bind to Smac (also known as
DIABLO), a protein that binds to and neutralises XIAP function
(Du et al., 2000; Verhagen et al., 2000). This shows that the S40D
protein is competent for some aspects of XIAP function but is
inhibited in its ability to bind activated effector caspases, indicating
that mitotic phosphorylation of XIAP at S40 restrains its ability to
inhibit caspase activity.
Modification of XIAPat S40 inhibits its anti-apoptotic activity
The inhibitory effect of the S40D mutation on the ability of XIAP to
bind active caspases strongly suggests that phosphorylation of S40
in XIAP regulates its anti-apoptotic activity. To test this possibility,
we first characterised the stability of wild-type and phosphorylation
site mutant GFP–XIAP proteins during interphase and mitotic
arrest. We found that GFP–XIAP S40A and S40D proteins, like the
wild-type protein, were expressed at a constant level during mitotic
arrest, indicating that the stability of the protein during mitosis was
not affected by phosphorylation at this site (Fig. 7A). Consistent
with results discussed above (Fig. 2D), phosphorylation of S40
detected by the specific antibody gradually increased over 2–6 h of
arrest (Fig. S3). Importantly, whereas expression of either the wild-
type XIAP or the S40A mutant strongly inhibited the induction of
apoptosis after prolonged treatment with nocodazole, the S40D
mutant was much less effective and produced no apparent inhibition
of apoptosis (Fig. 7B; Fig. S4A). The difference between the S40A
Fig. 5. XIAP is phosphorylated at S40 by CDK1–cyclin-
B1. (A) CDK1 kinase inhibitors suppress phosphorylation
of XIAP in vitro. Wild-type XIAP produced by coupled in
vitro translation and transcription (IVT XIAP) was
incubated with asynchronous (labelled A) or mitotic
nocodazole-treated (M) HeLa cell extracts with or without
kinase inhibitors purvalanol A (PA, 10 μM) and RO 3306
(RO, 10 μM). Lysates were analysed by PhosTag (PT)
SDS-PAGE and immunoblotted with anti-XIAP antibody.
(B) Wild-type (wt) IVT XIAP was incubated with
asynchronous (labelled A) or mitotic nocodazole-treated
(M) HeLa cell extracts at 30°C for 30 min with or without
kinase inhibitors. Wortmannin (W) was used at 0.1 μM,
and PA and RO were used as in A. IVT reticulocyte lysate
without vector DNA, HeLa extracts incubated alone, IVT
lysate without vector DNA incubated with HeLa extracts
and IVT S40A mutant incubated with HeLa extracts were
used as negative controls. Reactions were analysed by
SDS-PAGE and immunoblotted with pS40 XIAP antibody.
(C) S40 of XIAP is phosphorylated by CDK1–cyclin-B1.
Active recombinant GST-tagged CDK1–cyclin-B1 was
incubated with two different amounts of wild-type IVT XIAP
at 30°C for various times as indicated. IVT XIAP alone,
CDK1–cyclin-B1 alone and IVT XIAP incubated with HeLa
extracts were used as controls. Reactions were stopped by
the addition of 2× SDS lysis buffer. Samples were
analysed by SDS-PAGE and western blotting.
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and S40D proteins strongly suggests that phosphorylation of S40
inhibits the anti-apoptotic activity of XIAP. The similar effect of
wild-type and S40A XIAP expression is consistent with the
dominant inhibitory activity of the non-phosphorylated protein,
which is strongly elevated in both cases.
To determine whether modification of XIAP at S40 affects the
acute apoptotic response during mitosis when phosphorylation
occurs, we analysed the induction of cell death in individual
mitotic cells by live-cell imaging. U2OS cells arrested in mitosis by
250 ng/ml nocodazole were tracked for around 70 h after entry into
mitosis, by which time they had either slipped from mitosis,
blebbing transiently and flattening down as they entered interphase
(denoted survival), or had undergone rigorous blebbing followed by
stasis (mitotic cell death) (Fig. 7C; Fig. S4B). About 55% of control
cells transfected with an empty vector underwent mitotic cell death
and cells that expressed the S40D mutant of XIAP showed only a
slight reduction in cell death to 40% of control. By contrast, cells
expressing either wild-type of S40A mutant of XIAP showed a
strong reduction in mitotic cell death (<5% of control) (Fig. 7D),
indicating that phosphorylation of XIAP at S40 inhibits its activity
during mitosis and promotes mitotic cell death.
DISCUSSION
The induction of apoptosis during mitosis provides a mechanism to
selectively kill rogue cells that have failed to undergo chromosome
segregation successfully and on schedule. This pathway also
provides opportunities for the selective killing of cancer cells
through drugs that interfere with mitosis, including microtubule
poisons such as taxanes that prevent the proper attachment of
chromosomes to spindlemicrotubules and cause a prolonged arrest in
mitosis due to the activity of the spindle assembly (mitotic)
checkpoint. Importantly, there are distinct post-translational
mechanisms that control apoptosis during mitosis that facilitate
drug-induced cell killing, perhaps especially in cancer cells that have
sustained cellular stress but inwhich apoptosis is actively suppressed.
In this report, we have identified a mechanism that controls the
induction of cell death in mitotically arrested cells through the key
regulator XIAP. Our results indicate that phosphorylation of XIAP
at a single major site by the master mitotic kinase CDK1–cyclin-B
negates the ability of XIAP to bind to active effector caspases and
thereby reduces the threshold for apoptosis (Fig. 8). We show that
∼50% of the endogenous XIAP protein is phosphorylated at the
inhibitory site S40 (Fig. 3), suggesting that the remaining protein
that is not phosphorylated at this site continues to provide a restraint,
albeit reduced, so that when XIAP is completely removed, apoptosis
is increased further (Fig. 1). We propose that this mechanism is
important for the control of cell death during mitotic arrest, because
it reduces a downstream barrier to apoptosis once caspases-3 and -7
have been activated after proteolytic destruction of the upstream
regulator Mcl-1 (Harley et al., 2010; Wertz et al., 2011). The time-
dependent loss of Mcl-1 releases cytochrome c from mitochondria,
resulting in a pro-apoptotic signal that overwhelms the brake set by
inhibitory phosphorylation of caspase-9 (Allan and Clarke, 2007),
which is also activated by dephosphorylation as mitotic arrest
progresses (Harley et al., 2010). The inhibition of XIAP function by
phosphorylation would make mitotically arrested cells less resistant
to caspase activation and might explain the increased sensitivity of
such cells to BH3 mimetics that inhibit Mcl-1, Bcl-2 and Bcl-xL
(Colin et al., 2015; Shi et al., 2011). If cells survive mitotic arrest
and are released into interphase, dephosphorylation of XIAP would
restore its anti-apoptotic function and raise the threshold for
apoptosis again.
The sensitisation of mitotically arrested cells to apoptosis can be
hypothesised to actively remove cells that become severely delayed
in mitosis due to problems with chromosome segregation,
supernumerary centrosomes or even aneuploidy. This would
provide a mechanism to suppress the propagation of chromosome
abnormalities (Fig. 8). Cancer cells exhibiting such defects,
however, have presumably gone through a selection crisis in
which the mechanism of apoptosis during mitosis is actively
supressed. Two levels of the pathway at which this might well occur
are upon the overexpression of the anti-apoptotic Bcl-2 family
proteins, preventing cytochrome c release and caspase activation, or
upon XIAP overexpression, blocking the action of caspases. At
present it is unclear whether aberrant changes in the post-
translational regulation of these components also contribute to the
suppression of mitotic cell death in cancer cells, but if this is the case
then targeting these mechanisms could activate apoptosis
particularly well in such stressed cells.
The regulation of XIAP by CDK1–cyclin-B1 illustrates the close
integration of the control of apoptosis with the progression of
mitosis. In addition to XIAP, Mcl-1 is destroyed by proteolysis
following phosphorylation byCDK1–cyclin-B1 (Harley et al., 2010;
Wertz et al., 2011), and the related anti-apoptotic proteins Bcl-2 and
Bcl-xL might be directly inhibited by mitotic phosphorylation
(Terrano et al., 2010). Opposing these pro-apoptotic events, we have
shown that caspase-9 is inhibited by phosphorylation during normal
mitosis and in the early stages of mitotic arrest (Allan and Clarke,
2007). The importance of the inhibition of XIAP by mitotic
phosphorylation might be that it removes a downstream brake on
apoptosis, resulting in one major point of regulation (caspase-9
activation) that permits the induction of apoptosis after a prolonged
arrest. Anti-cancer drugs that target mitotic cells appear to exploit
Fig. 6. The ability of XIAP to bind cleaved effector caspases is inhibited by
mutation of S40 to a phosphomimetic aspartate residue. HeLa S100
extract was incubated with cytochrome c and dATP to induce caspase
cleavage prior to incubation with GFP–XIAP precipitated from cells stably
expressing GFP–XIAP S40A or S40D protein. GFP–XIAP was recovered from
the extract and co-precipitating proteins were detected by western blotting
using the indicated antibodies. Cell lysates and HeLa cell S100 reactions were
analysed for comparison.
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this mechanism to initiate mitosis by arresting or delaying them in
mitosis long enough to overcome the temporal restraint to caspase
activation. Cells that do not undergo full apoptosis from the mitotic
state nevertheless carry a signal caused by caspase-dependent DNA
damage that can subsequently determine long-term cell fate after
release into interphase even though a higher threshold for apoptosis
has been restored (Colin et al., 2015) (Fig. 8). Our results further
emphasise that cell death during mitosis is a form of caspase-
dependent apoptosis, albeit one under mitosis-specific post-
translational controls.
MATERIALS AND METHODS
Cell culture and cell extracts
HeLa (Ohio) and U2OS (HTB96) cell lines were obtained from Cancer
Research UK Laboratories, London, UK. HCT116 parental and XIAP-
knockout cell lines were purchased from Horizon Discovery Ltd.,
Cambridge, UK. All cell lines were confirmed as negative for
mycoplasma infection. Cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen) supplemented with 10% (v/v) fetal
bovine serum (Biosera) and 1% (v/v) penicillin-streptomycin (Invitrogen) at
37°C and in 5% CO2. U2OS cells stably expressing GFP–XIAP proteins
were generated by transfection with pEGFP-XIAP vector containing a G418
Fig. 7. Mutation of S40 in XIAP to a
phosphomimetic aspartate residue
inhibits its ability to protect cells
against apoptosis induced by
prolonged mitotic arrest. (A,B) Cell
death following mitotic arrest is not
inhibited by expression of XIAP S40D
protein. U2OS cells that were
untransfected (Unt), stably expressing
GFP-tagged wild-type (wt), S40A or
S40D mutant XIAP protein were treated
with 250 ng/ml nocodazole for 48 h. All
cells were collected at the end of the
timecourse and either (A) lysed,
analysed by SDS-PAGE and western
blotting (representative blots are
shown) or (B) fixed and stained with
propidium iodide for sub-G1 analysis
using flow cytometry (n=3). In B, results
are mean±s.d. **P<0.005; NS, non-
significant difference (Student’s
unpaired t-test). (C,D) XIAP S40D fails
to restrain apoptosis during mitotic
arrest. Cells stably expressing GFP-
tagged wild-type (wt), S40A or S40D
mutant XIAP protein were treated with
250 ng/ml nocodazole. Cell fate
following mitotic entry wasmonitored by
time-lapse microscopy. (C)
Representative images of cells
expressing S40A or S40D mutant XIAP
are shown. Examples of cells
undergoing slippage (open arrows) or
mitotic cell death (full arrows) are
indicated. Scale bars: 50 µm.
(D) Quantification of mitotic cell death in
cell lines depicted in C, control cells
(Ctrl) and cells expressing wild-type
XIAP (wt). For each experiment (n=3),
the fate of 50 cells was assessed.
Results are mean±s.d. **P<0.01;
****P<0.0001; NS, non-significant
difference (Student’s unpaired t-test).
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resistance marker. Cells were grown for 2–3 weeks with 800 µg/ml G418
Geneticin (Invitrogen) and maintained in 400 µg/ml G418. Cell extracts
were prepared from mitotic or asynchronous HeLa cells at a protein
concentration of 6–10 mg/ml in EBS (80 mM β-glycerophosphate-HCl
pH 7.2, 20 mM EGTA, 15 mM MgCl2, 100 mM sucrose, 1 mM DTT,
1 mM PMSF) as described previously (Harley et al., 2010). HeLa cell
cytosolic S100 extracts were supplied at a protein concentration of 8 mg/ml
in extract buffer (10 mM Hepes-KOH pH 8.5, 10 mM KCl, 10 mMMgCl2,
0.5 mM DTT) (Computer Cell Culture Centre, Mons, Belgium).
XIAP knock down by siRNA
Four RNA oligonucleotides that made up the siGENOME SMARTpool
XIAP siRNA (Thermo Fisher Scientific) were tested individually. Two of
the four oligonucleotides that resulted in the most efficient depletion of
XIAP were used together in future experiments. The two XIAP siRNA
oligonucleotides and the luciferase control siRNA were: XIAP siRNA 1,
5′-GCACGGAUCUUUACUUUG-3′; XIAP siRNA 2, 5′-GAACUGGG-
CAGGUUGUAGA-3′; and luciferase siRNA, 5′-CGUACGCGGAAUA-
CUUCGATT-3′.
U2OS cells were transfected with the oligonucleotides using
Lipofectamine 2000 (Invitrogen) and incubated for 48 h. 250 ng/ml
nocodazole was then added for a further 48 h as required.
Western blotting
Antibodies were used as described in Table S1.
Generation of a polyclonal antibody specific for XIAP
phosphorylated at S40
Rabbits were inoculated with the phosphorylated peptide
FANFPSGS*PVSASTL (where S* represents the phosphorylated residue)
byMoravian Biotechnology. A phospho-specific antibody, pS40XIAP, was
purified from the serum obtained after a second inoculation on a column of
phosphorylated peptide coupled to Reactigel beads (Pierce Biotechnology),
eluted with 0.1 M glycine-HCl (pH 2.5), which was neutralised with the
addition of 1.5 M Tris-HCl (pH 8.5) supplemented with 100 µg/ml BSA,
50% glycerol and 0.05% sodium azide, and stored at −20°C.
Phosphorylated or non-phosphorylated peptide was coupled to
immunoglobulin-free BSA (Sigma-Aldrich) using 50% (w/v)
glutaraldehyde solution (Sigma-Aldrich) diluted in PBS. The BSA-
conjugated peptide solutions were serially diluted in PBS, spotted onto
nitrocellulose membrane and air-dried before being incubated in western
blocking buffer. They were then incubated with 1:500 diluted phospho-
specific antibody overnight at 4°C, followed by washes and secondary
antibody probing.
Detection of active caspase-3
Cells on coverslips or glass slides were permeabilised by incubating in ice-
cold 80% ethanol for 15 min, and followed by two washes in PBS. Cells
were blocked in 5% BSA and 0.2% Triton X-100 in PBS for 20 min at room
temperature, before they were incubated with anti-cleaved caspase-3
antibody (cat. no. 9661, Cell Signaling) at a 1:400 dilution in 1% BSA
and 0.2% Triton-X-100 in PBS at room temperature for 1 h. After two 5-min
washes with 0.2% Triton X-100 in PBS on a rotary shaker, cells were
incubated with 1:200 diluted TRITC-conjugated anti-rabbit-IgG secondary
antibody (cat. no. R0156, Dako) and 250 ng/ml DAPI (Sigma) in 1% BSA
and 0.2% Triton X-100 in PBS in the dark at room temperature for 1 h. This
was followed by two 5-min washes with 0.2% Triton X-100 in PBS and one
5-min wash with PBS on a rotary shaker. Slides were mounted with
mounting medium (Dako), air dried and kept at 4°C in the dark until they
were viewed under the microscope.
Microscopy
Fixed cells were visualised using Zeiss Axiovert 100 microscope with
specific filters for the excitation of fluorophores. Images were taken at 63×
magnification using Openlab software. For live-cell imaging, cells were
imaged every 10 min in a heated chamber on a Zeiss Axiovert 200 M
microscope. Images were acquired using a C4742-80-12AG camera
(Hamamatsu) and µmanager software and were processed using ImageJ
Fiji. Analysis was carried out on cells that were arrested in mitosis for at least
6 h with cell death being defined by cell morphology and cessation of
movement.
Flow cytometry
Cells stained with propidium iodide were analysed on a FACS flow
cytometer (Becton Dickinson) on the FL3 channel. A minimum of 104 cells
were analysed for each sample. Data were displayed as dot plots and
histograms showing the cell cycle phases and sub-G1 population using
FlowJo software.
GFP–XIAP precipitation from cells
U2OS cells stably expressing GFP or GFP–XIAP were treated with
100 ng/ml nocodazole for 17 h. The asynchronous cells from the untreated
plate and the mitotically arrested cells from the nocodazole-treated
plates were washed twice in cold PBS, and lysed in cold GFP lysis buffer
(10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 5 mM
β-glycerophosphate, 50 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 1 µg/ml
each of aprotinin, leupeptin and pepstatin A, 0.2% CHAPS). The protein
concentration of the lysates was adjusted to 1 mg/ml with GFP lysis buffer.
300 µg lysate was mixed with 10 µl pre-washed GFP-Trap beads
(ChromoTek) for each sample, and incubated at 4°C for 1 h on a rotator.
The beads were pelleted by centrifugation at 4°C, washed once with GFP
lysis buffer followed by two washes with 10 mM Tris-HCl (pH 7.5).
Samples were analysed by SDS-PAGE and western blotting.
Fig. 8. Role of XIAP in determining cell fate during mitotic arrest. CDK1–
cyclin-B1 drives cells into mitosis and controls the induction of apoptosis by
inhibitory phosphorylation of XIAP. After the last unattached kinetochore is
correctly attached to spindle microtubules and the chromosomes are properly
aligned, the spindle assembly or mitotic checkpoint (MC) is switched off. CDK1
is then inactivated as cyclin B1 is rapidly degraded, and cells progress through
anaphase, undergo cytokinesis and exit mitosis. In the presence of an anti-
mitotic drug, such as a microtubule poison, the checkpoint cannot be satisfied
and cells are arrested for a prolonged period. Arrested cells might undergo cell
death or can slip out of mitosis due to the slow degradation of cyclin B1 and
undergo a variety of alternative cell fates. Phosphorylation of XIAP reduces the
threshold for apoptosis during mitotic arrest. However, when a cell exits mitosis
normally or slips out of mitotic arrest, XIAP is reactivated by dephosphorylation
and contributes to cell survival.
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In vitro phosphorylation assays
GST–XIAP was expressed from the pGEX-6P-1 vector in E.coli BLR(DE3)
competent cells (Novagen), purified on Glutathione–Sepharose 4B beads
(Amersham) and stored in 10 mM Hepes-KOH (pH 7.5), 150 mM NaCl,
0.07% β-mercaptoethanol. In vitro translated and transcribed (IVT) XIAP was
produced using the TNT Quick Coupled Transcription/Translation system
(Promega) using XIAP inserted in the pcDNA3.2/V5-DEST vector. Either
50 ng of GST–XIAP or 3 µl IVT XIAP was incubated with 1 µl mitotic HeLa
EBSextract in phosphorylation reaction buffer (50 mMTris-HClpH7.5, 1 mM
DTT) plusMgATP (0.1 mMATP, 10 mMMgCl2, 5 mMHepes-KOHpH 7.5)
at 30°C for 30 min in a total reaction volume of 10 µl. For phosphorylation by
CDK1–cyclin-B1, 25 ng active recombinant kinase (Millipore) replaced HeLa
extract. Where specified, 1 U/µl calf intestinal phosphatase (CIP) (Roche) and
1 µl of 10× CIP reaction buffer (0.5 M Tris-HCl pH 8.5, 1 mMEDTA), 1 µl of
10× ATP-regenerating system (0.1 mg/ml creatine kinase and 50 mM creatine
phosphate) or kinase inhibitors were added. After incubation, reactions were
stopped by addition of an equal volume of 2× SDS lysis buffer, 5% β-
mercaptoethanol and 0.05% Bromophenol Blue. Owing to the presence of
EGTA in the cell extract EBS buffer, which would interfere with PhosTag
reagent, an equal molar concentration of MnCl2 was added to the loading
samples that were going to be tested on PhosTag gels. Samples were boiled for
4 min, then analysed by SDS-PAGE and western blotting.
In vitro binding assay
HeLa S100 extract (4 mg) was incubated with 10 µM cytochrome c
and 1 mM dATP together with an ATP-regenerating system (1 mM ATP,
10 µg/ml creatine kinase and 5 mM creatine phosphate) at 30°C for 3 h.
U2OS cells stably expressing GFP–XIAP S40A or S40D were lysed in
GFP-Trap buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA
and 0.5% NP40). A total of 2 mg lysate was diluted 2:3 with dilution buffer
(GFP-Trap buffer without NP40) and incubated with 25 µl GFP-TrapM
beads (ChromoTek), 4°C, 1 h with rotation. Beads were isolated using a
magnet (BioRad) and washed three times in GFP-Trap buffer diluted as
above followed by one wash in dilution buffer. GFP–XIAP beads were then
incubated with S100, cytochrome c and dATP reactions at room temperature
for 90 min with rotation. Beads were then isolated, washed as above and
boiled in SDS gel-loading buffer.
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